More Questions About Aspartame

WebMD reports an Italian study of rats links low doses of aspartame -- the sweetener in NutraSweet, Equal, and thousands of consumer products -- to leukemia and lymphoma. But food industry officials point out that many other studies have found no link between aspartame and cancer.



The rats in the study were fed various doses of aspartame throughout their lives. In female but not male rats, lymphoma and leukemia were significantly associated with daily aspartame doses as low as 20 milligrams (mg) per kilogram (kg) of body weight. To reach a dose of 20 mg/kg, a 140-pound woman would need to drink three cans of diet soda a day. A 180-pound man would need to drink four cans of diet soda a day. The sweetener is also in thousands of products, ranging from yogurt to over-the-counter medicines.



The average person consumes about 2 or 3 mg/kg aspartame each day. However, that figure goes way up for children and young women. The study comes from a research team led by Morando Soffritti, MD, scientific director of the European Ramazzini Foundation of Oncology and Environmental Sciences in Bologna, Italy.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap